ArticleEuropean journal of cancer (Oxford, England : 1990)2017
Societal challenges of precision medicine: Bringing order to chaos.
Article in European journal of cancer (Oxford, England : 1990), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence.Biomedicines · 2025Article
- Strategies for discovering novel hepatocellular carcinoma biomarkers.World journal of hepatology · 2025Review
- Identification and Validation of Key Genes Related to Lipophagy in Osteoporosis.Orthopedic research and reviews · 2025Article
- The Biomarker Toolkit - an evidence-based guideline to predict cancer biomarker success and guide development.BMC medicine · 2023Article
- Gene therapy for selected neuromuscular and trinucleotide repeat disorders - An insight to subsume South Asia for multicenter clinical trials.IBRO neuroscience reports · 2023Article
- Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making.Frontiers in pharmacology · 2020Article
- Precise Immunodetection of PTEN Protein in Human Neoplasia.Cold Spring Harbor perspectives in medicine · 2019Review
- Late translational research: putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society.Molecular oncology · 2019Review
- Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.Diabetes, obesity & metabolism · 2018Review
- Biomarkers in early-phase trials: fundamental issues.Bioanalysis · 2018Article
- Epidemiology in wonderland: Big Data and precision medicine.European journal of epidemiology · 2018Article
- Biosignature Discovery for Substance Use Disorders Using Statistical Learning.Trends in molecular medicine · 2018Review
- Tumor Pre-Analytics in Molecular Pathology: Impact on Protein Expression and Analysis.Current pathobiology reports · 2018Review
- Steps forward for cancer precision medicine.Nature reviews. Drug discovery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 5 countries.
Funding
Abstract
The increasing number of drugs targeting specific proteins implicated in tumourigenesis and the commercial promotion of relatively affordable genome-wide analyses has led to an increasing expectation among patients with cancer that they can now receive effective personalised treatment based on the often complex genomic signature of their tumour. For such approaches to work in routine practice, the development of correspondingly complex biomarker assays through an appropriate and rigorous regulatory framework will be required. It is becoming increasingly evident that a re-engineering of clinical research is necessary so that regulatory considerations and procedures facilitate the efficient translation of these required biomarker assays from the discovery setting through to clinical application. This article discusses the practical requirements and challenges of developing such new precision medicine strategies, based on leveraging complex genomic profiles, as discussed at the Innovation and Biomarkers in Cancer Drug Development meeting (8th-9th September 2016, Brussels, Belgium).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.